Ifenprodil for the treatment of methamphetamine use disorder: An exploratory, randomized, double‐blind, placebo‐controlled trial
Open Access
- 23 January 2022
- journal article
- research article
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 42 (1) , 92-104
Abstract
Aim No effective pharmacological interventions have been developed for patients with methamphetamine use disorder. Ifenprodil is a blocker of G protein-activated inwardly rectifying potassium channels, which play a key role in the mechanism of action of addictive substances. We conducted a randomized, double‑blind, exploratory, dose-ranging, placebo-controlled trial to examine the clinical efficacy of ifenprodil for the treatment of methamphetamine use disorder. Methods Participants were assigned to three groups: placebo, 60 mg/d ifenprodil, or 120 mg/d ifenprodil. The drug administration period was 84 days. The primary outcome was the use or nonuse of methamphetamine during the drug administration period in the placebo group vs 120 mg/d ifenprodil group. We also assessed drug use status, relapse risk based on the Stimulant Relapse Risk Scale (SRRS), drug craving, and methamphetamine in urine as secondary outcomes. We further evaluated drug use status and SRRS subscale scores in patients who were not taking addiction medications during the study. Results Ifenprodil did not affect the primary or secondary outcomes. However, the additional analyses showed that the number of days of methamphetamine use during the follow-up period and scores on the emotionality problems subscale of the SRRS improved in the 120 mg/d ifenprodil group. The safety of ifenprodil was confirmed in patients with methamphetamine use disorder. Conclusion The present findings did not confirm the efficacy of ifenprodil for methamphetamine use disorder treatment based on the primary or secondary outcomes, but we found evidence of its safety and efficacy in reducing emotionality problems. Clinical trial registration The study was registered at the University Hospital Medical Information Network Clinical Trial Registry (no. UMIN000030849) and Japan Registry of Clinical Trials (no. jRCTs031180080). The main registration site is jRCT (https://jrct.niph.go.jp/).Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP18dk0307071)
- Mitsubishi Foundation (ID30314)
- Smoking Research Foundation
This publication has 42 references indexed in Scilit:
- Psychopathology in methamphetamine‐dependent adults 3 years after treatmentDrug and Alcohol Review, 2010
- Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependenceAddiction, 2009
- Depression Among Methamphetamine UsersJournal of Nervous & Mental Disease, 2009
- Development and validation of the Stimulant Relapse Risk Scale for drug abusers in JapanDrug and Alcohol Dependence, 2007
- Fluoxetine as a Potential Pharmacotherapy for Methamphetamine DependenceAnnals of the New York Academy of Sciences, 2006
- Inhibition of G Protein-Activated Inwardly Rectifying K+ Channels by IfenprodilNeuropsychopharmacology, 2005
- Clinical Features of Sensitization to Methamphetamine Observed in Patients with Methamphetamine Dependence and PsychosisAnnals of the New York Academy of Sciences, 2004
- Molecular Cloning of a Mouse G-Protein-Activated K+ Channel (mGIRK1) and Distinct Distributions of 3 GIRK (GIRK1, 2 and 3) mRNAs in Mouse BrainBiochemical and Biophysical Research Communications, 1995
- The G-protein-gated atrial K+ channel IKAch is a heteromultimer of two inwardly rectifying K+-channel proteinsNature, 1995
- Separation of .alpha.1-adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compoundsJournal of Medicinal Chemistry, 1991